PXS-6302 / Syntara - LARVOL DELTA

The SATELLITE study: A Phase 1c Study Investigating the SAfety and TolErability of a LysyL Oxidase InhibiTor (PXS-6302) in the amElioration of Keloids (ANZCTR) - P1 | N=20 | Recruiting | Sponsor: University of Western Australia | Not yet recruiting ➔ Recruiting

Enrollment open • Trial initiation date • Fibrosis

A randomized, double-blind, placebo-controlled phase 1 trial of the topical pan-lysyl oxidase inhibitor PXS-6302 in mature scars. (PubMed, Sci Transl Med) - P1/2 | "No significant differences in Patient Observer Scar Assessment Scale (POSAS) scores were observed between groups after 90 days of treatment once baseline imbalances were accounted for. Together, these data showed that topical pan-lysyl oxidase inhibition was generally well tolerated and altered some measures of the ECM in mature scars, supporting the advancement of this treatment into phase 2 trials."

Clinical • Journal • P1 data

A Phase 1c Study Investigating the SAfety and TolErability of a LysyL Oxidase InhibiTor (PXS-6302) in the amElioration of Keloids (ANZCTR) - P1 | N=20 | Not yet recruiting | Sponsor: University of Western Australia

New P1 trial • Fibrosis

The topical application of PXS-6302 ameliorates skin scarring and fibrosis (WCD 2023) - "Bleomycin-induced skin fibrosis and full-thickness excision injury murine models were used to study the anti-fibrotic and scar amelioration efficacy. PXS-6302 presents a promising new therapeutic to ameliorate scar formation"

Fibrosis • Immunology

Topical application of an irreversible small molecule inhibitor of lysyl oxidases ameliorates skin scarring and fibrosis. (PubMed, Nat Commun) - "Topical application of PXS-6302 after injury also significantly improves scar appearance without reducing tissue strength in porcine injury models. PXS-6302 therefore represents a promising therapeutic to ameliorate scar formation, with potentially broader applications in other fibrotic diseases."

Journal • Fibrosis • Immunology